NeoGenomics director exercises options, gets new grants

NeoGenomics, Inc. director Felicia Williams reported multiple equity compensation events.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

NeoGenomics, Inc. director Felicia Williams reported multiple equity compensation events. She exercised previously granted restricted stock units, receiving 23,077 shares of common stock at a price of $0.00 per share, and now directly owns 30,237 common shares following the transactions.

She was also granted 15,970 restricted stock units and 11,069 stock options with an exercise price of $10.52 per share, both relating to NeoGenomics common stock. In addition, she continues to hold options covering 16,107 shares at an exercise price of $7.28 per share expiring June 1, 2035, and 5,430 shares at $13.59 per share expiring June 1, 2034.

Insider Trade Summary

23,077 shares exercised/converted

Exercise 6 txns

Insider Williams Felicia

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	23,077	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	11,069	$0.00	$0.00
Grant/Award	Restricted Stock Unit	15,970	$0.00	$0.00
Exercise	Common Stock	23,077	$0.00	$0.00
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--

Holdings After Transaction: Restricted Stock Unit — 15,970 contracts (Direct); Stock Option (Right to Buy) — 32,606 contracts for 21,537 underlying shares (Direct); Common Stock — 30,237 shares (Direct)

Footnotes (2)

F1. Reflects release of restricted stock units that were previously reported on a Form 4.
F2. Once vested, the shares of common stock are not subject to expiration.

Key Figures

RSU shares exercised: 23,077 shares Common shares owned after transactions: 30,237 shares New RSU grant: 15,970 units +3 more

6 metrics

RSU shares exercised 23,077 shares Common stock received from RSU vesting on June 1, 2026

Common shares owned after transactions 30,237 shares Direct NeoGenomics common stock holdings following Form 4

New RSU grant 15,970 units Restricted stock units granted June 1, 2026

New stock option grant 11,069 options at $10.52 Options exercisable for NeoGenomics common stock, expiring June 1, 2036

Existing option position 1 16,107 shares at $7.28 Stock options expiring June 1, 2035

Existing option position 2 5,430 shares at $13.59 Stock options expiring June 1, 2034

Key Terms

Restricted Stock Unit, Stock Option (Right to Buy), derivative security

3 terms

Restricted Stock Unit financial

"Restricted Stock Unit transactions involved 23,077 and 15,970 underlying common shares."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) awards cover underlying NeoGenomics common stock."

derivative security financial

"Exercise or conversion of derivative security is indicated by transaction code M."

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did NeoGenomics (NEO) director Felicia Williams report?

Felicia Williams reported exercising previously granted restricted stock units for 23,077 common shares and receiving new grants of 15,970 restricted stock units and 11,069 stock options. All positions relate to NeoGenomics common stock and are held as direct ownership.

How many NeoGenomics (NEO) common shares does Felicia Williams own after this Form 4?

After these transactions, Felicia Williams directly owns 30,237 NeoGenomics common shares. This balance reflects the 23,077 shares received from the vesting and conversion of restricted stock units on June 1, 2026, along with her prior holdings.

What new equity awards did Felicia Williams receive from NeoGenomics (NEO)?

She received 15,970 restricted stock units and 11,069 stock options tied to NeoGenomics common stock. The new stock options have an exercise price of $10.52 per share and an expiration date of June 1, 2036, according to the filing data.

What stock options does Felicia Williams hold in NeoGenomics (NEO) after the filing?

She holds options on 16,107 shares at an exercise price of $7.28 expiring June 1, 2035, and 5,430 shares at $13.59 expiring June 1, 2034. She also has a new grant of 11,069 options at $10.52 per share expiring June 1, 2036.

How many restricted stock units in NeoGenomics (NEO) vest or remain for Felicia Williams?

Previously granted restricted stock units covering 23,077 shares were released and converted into common stock. She now has a new award of 15,970 restricted stock units, each representing one share of NeoGenomics common stock upon future vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/03/2026 - 07:47 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Williams Felicia

(Last)

(First)

(Middle)

9490 NEOGENOMICS WAY

(Street)

FORT MYERS

FLORIDA

33912

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEOGENOMICS INC [ NEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/01/2026		M		23,077⁽¹⁾	A	$0	30,237	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	$0	06/01/2026		M			23,077	06/01/2026	⁽²⁾	Common Stock	23,077	$0	0	D
Stock Option (Right to Buy)	$10.52	06/01/2026		A		11,069		06/01/2027	06/01/2036	Common Stock	11,069	$0	11,069	D
Restricted Stock Unit	$0	06/01/2026		A		15,970		06/01/2027	⁽²⁾	Common Stock	15,970	$0	15,970	D
Stock Option (Right to Buy)	$13.59							06/01/2025	06/01/2034	Common Stock	5,430		5,430	D
Stock Option (Right to Buy)	$7.28							06/01/2026	06/01/2035	Common Stock	16,107		16,107	D

Explanation of Responses:

1. Reflects release of restricted stock units that were previously reported on a Form 4.

2. Once vested, the shares of common stock are not subject to expiration.

Remarks:

	/s/ Ali Olivo, Attorney-in-Fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR